{
    "clinical_study": {
        "@rank": "70342", 
        "arm_group": {
            "arm_group_label": "AKB-9778", 
            "arm_group_type": "Experimental", 
            "description": "Up to 4 dose levels of subcutaneous AKB-9778 will be evaluated. Doses will be administered daily for 28 days."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and\n      pilot efficacy of multiple ascending dose levels of AKB-9778 given as subcutaneous\n      injections daily for 28 days in patients with diabetic macular edema (DME)."
        }, 
        "brief_title": "Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Macular Edema (DME)", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        The following is an abbreviated list of inclusion criteria:\n\n          -  Adults between 18 to 80 years of age, inclusive\n\n          -  Diagnosis of diabetes mellitus (type 1 or type 2)\n\n          -  Decrease in vision determined to be primarily the result of DME in the study eye\n\n          -  Definite Retinal thickening due to diffuse DME involving the center of the macula in\n             the study eye\n\n          -  Mean central subfield thickness of at least 325 \u00b5m by OCT in the study eye\n\n          -  Early Treatment Diabetic Retinopathy Study (ETDRS) letter score BCVA \u2264 70 (20/40) in\n             the study eye\n\n        Exclusion Criteria:\n\n        The following is an abbreviated list of exclusion criteria:\n\n          -  Hemoglobin A1C (HbA1C) \u2265 11.5%\n\n          -  History of any of the following in the study eye (however, the following are not\n             exclusionary in the fellow eye):\n\n               1. Panretinal scatter photocoagulation (PRP) or focal laser within 12 weeks prior\n                  to Screening\n\n               2. Prior pars plana vitrectomy within 12 weeks prior to Screening\n\n               3. Any ocular surgery within 12 weeks prior to Screening\n\n               4. YAG capsulotomy within 7 days prior to Screening\n\n               5. Prior intravitreal, subtenon, or periocular steroid therapy within 3 months\n                  prior to Screening or prior treatment with intravitreal anti-VEGF treatment\n                  within 1 month of Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702441", 
            "org_study_id": "AKB-9778-CI-2002"
        }, 
        "intervention": {
            "arm_group_label": "AKB-9778", 
            "intervention_name": "Subcutaneous AKB-9778", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winter Haven", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1b/2a Open Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28 Day Repeat Subcutaneous Doses of AKB-9778 in Subjects With Diabetic Macular Edema", 
        "overall_official": {
            "affiliation": "Aerpio Therapeutics", 
            "last_name": "Kevin Peters, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence and severity of adverse events (AEs).", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Change from baseline in physical exams.", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Change from baseline in vital signs.", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Change from baseline in electrocardiograms (ECGs).", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Change from baseline in opthalmic exams.", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Blood chemistry, hematology and urinalysis.", 
                "measure": "Change from baseline in clinical laboratory assay results.", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702441"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maximum plasma drug concentration (Cmax). Area under the plasma concentration-time curve (AUC).", 
                "measure": "Pharmacokinetics of AKB-9778", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 and Day 14"
            }, 
            {
                "measure": "Change from baseline in optical tomography (OCT)-measured retinal thickness.", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Change from baseline in best corrected visual acuity (BCVA).", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }
        ], 
        "source": "Aerpio Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aerpio Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}